Research programme: anticancer fleximer antibody-drug conjugates - Asana BioSciences

Drug Profile

Research programme: anticancer fleximer antibody-drug conjugates - Asana BioSciences

Alternative Names: ASN 004; Dolaflexin® ADC - Asana BioSciences; Fleximer® - ADC - Endo Pharmaceuticals/Mersana Therapeutics

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Endo Pharmaceuticals
  • Developer Asana BioSciences
  • Class Antineoplastics; Depsipeptides; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Mar 2017 Mersana Therapeutics has patent protection for Fleximer-ADC platform technology in the European Union
  • 17 Oct 2013 Preclinical trials in Cancer in USA
  • 07 Mar 2012 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top